![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AstraZeneca’s Once-a-Week Diabetes Drug Approved for Children
AstraZeneca’s Once-a-Week Diabetes Drug Approved for Children
![AstraZeneca](https://www.fdanews.com/ext/resources/test/Device_Images2/AstraZeneca.gif?t=1576126438&width=430)
The FDA has approved AstraZeneca’s once-a-week injectable diabetes drug, Bydureon BCise (exenatide extended-release), for use in children age 10 years and older.
Bydureon BCise was previously approved by the agency for lowering blood sugar in adults with type 2 diabetes, in addition to other oral medicines, diet and exercise.
Bydureon BCise is part of a diabetes drug class known as glucagon-like peptide-1 agonists, which boost insulin levels in the body when blood sugar levels are elevated.
The drug has also received marketing authorization in the EU.
Upcoming Events
-
21Oct